Colloquium: Paul Schaffer
Life in a Physics Lab: Applying Particle Accelerator Technology to Study Life From its inception, the Life Sciences division at TRIUMF has leveraged the laboratory’s extensive particle accelerator expertise and infrastructure to explore novel technology to better understand life at the molecular level. While the production of short-lived (half-life <2 hr) positron emitting isotopes and radiopharmaceuticals has long provided a foundation for the division’s interdisciplinary science program, access to TRIUMF’s 13 to 500 MeV proton cyclotrons, and an anticipated 30 MeV elinac, has led to the development of a new suite of imaging isotopes, including Tc-99m, Tc-94m, Sc-44, Y-86, Zr-89 and Ga-68 using novel target production technology. Paul Schaffer, associate lab director of the Life Sciences Division at TRIUMF, will present a summary of efforts to produce various metallic isotopes using both liquid and solid target types, followed by a discussion on the production of various alpha- (Ac-225, Bi-213, At-211) and Auger- (Sb-119) emitting isotopes for therapeutic applications; some of which are now entering clinical trials.Emerging research efforts have also recently expanded beyond isotope production and include programs that leverage and apply TRIUMF’s Isotope Separation On-Line (ISOL), NMR and proton therapy facilities to study biological systems, and treat disease with unprecedented sensitivity and accuracy. This seminar will conclude with an overview of TRIUMF’s upcoming five-year plan (2020-2025), and efforts to construct and operate the Advanced Rare IsotopE Laboratory (ARIEL), as well as the new Institute for Advanced Medical Isotopes (IAMI). Several examples of technology commercialization will also be highlighted.